| Description | Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production. |
| In vivo | Avatrombopag is treatment of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure[1]. |
| Target activity | TPO receptor:3.3 nM (EC50) |
| Synonyms | YM477, AKR-501, 1-[3-氯-5-[[[4-(4-氯-2-噻吩基)-5-(4-环己基-1-哌嗪基)-2-噻唑基]氨基]羰基]-2-吡啶基]-4-哌啶羧酸, E5501 |
| molecular weight | 649.65 |
| Molecular formula | C29H34Cl2N6O3S2 |
| CAS | 570406-98-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: < 1mg/ml (insoluble） |
| References | 1. Xu H, Cai R.Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.Expert Rev Clin Pharmacol. 2019 Sep;12(9):859-865 2. Al-Samkari H.Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.Drugs Today (Barc). 2018 Nov;54(11):647-655. |